AI Article Synopsis

  • - Alzheimer's disease (AD) is a growing health challenge, especially in developed countries, due to longer life expectancies, but currently lacks a standard method for early diagnosis and effective treatment options.
  • - The monoclonal antibody lecanemab has opened up new possibilities for drug development and has sparked interest in small molecules, which could be simpler, cheaper, and easier for patients to use at home.
  • - Small-molecule near-infrared fluorescent theranostics are attracting attention for their dual role in diagnosing and treating AD, potentially replacing expensive methods and paving the way for personalized medicine in patients.

Article Abstract

Alzheimer's disease (AD) is the most common form of neurodegenerative dementia that is rapidly becoming a major health problem, especially in developed countries because of their increasing life expectancy. Two main problems are often associated with the disease: (i) the absence of a widely accessible "gold-standard" for early diagnosis and (ii) lack of effective therapies with disease-modifying effects. The recent success of the monoclonal antibody lecanemab played an important role not only in clarifying a possible druggable pathway but also in spelling the revival of small molecule drug discovery. Unlike bulky biologics, small molecules are structurally less complex, generally cheaper, and compatible with at-home oral consumption, making it feasible for people to start their drug regimen early and stay on it longer. In this sense, small-molecule near-infrared fluorescent theranostics have been gaining more and more attention from the scientific community, as they have the potential to simultaneously provide diagnostic outputs and deliver therapeutic action, paving the way toward personalized medicine in AD patients. They also have the potential to shift the diagnostic "status-quo" from expensive and limited-access PET radiotracers toward inexpensive and handy imaging tools widely available for primary patient screening and preclinical animal studies. Herein, we review the most recent advances in the field of fluorescent theranostics for Alzheimer's disease, detailing their design strategies, synthetic approaches and imaging and therapeutic properties and . With this Review, we intend to provide a milestone in the acquired knowledge in the field of AD theranostics, encouraging the future development of properly designed theranostic compounds with improved chances to reach clinical applications.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10975685PMC
http://dx.doi.org/10.1021/acsomega.3c10417DOI Listing

Publication Analysis

Top Keywords

fluorescent theranostics
12
alzheimer's disease
12
theranostics alzheimer's
8
advances fluorescent
4
theranostics
4
disease
4
disease comprehensive
4
comprehensive survey
4
survey design
4
design synthesis
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!